1. Volume 94, Issue 3, Pages 589-598 (September 2018)
DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients 
Angelo Karaboyas, Hairong Xu, Hal Morgenstern, Francesco Locatelli, Michel Jadoul, Kosaku Nitta, Indranil Dasgupta, Francesca Tentori, Friedrich K. Port, Bruce M. Robinson 
Kidney International 
Volume 94, Issue 3, Pages (September 2018)
DOI: /j.kint
Copyright © 2018 International Society of Nephrology Terms and Conditions

2. Figure 1
Renin angiotensin-aldosterone system inhibitors (RAASi) prescription by region, Dialysis Outcomes and Practice Patterns Study (DOPPS) phase, and time on dialysis. “Other” includes any patients prescribed a RAASi other than an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). A/NZ, Australia/New Zealand. *DOPPS phase 2: 2002–2004; phase 3: 2005–2008; phase 4: 2009–2011; phase 5: 2012–2015; **Incident, on dialysis ≤120 days at study entry; prevalent, on dialysis >120 days at study entry.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

3. Figure 2
Associations between antihypertensive medications and mortality in (a) incident dialysis patients and (b) prevalent dialysis patients. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio. *Incident, on dialysis ≤120 days at study entry; prevalent, on dialysis >120 days at study entry.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions